Recent failures in antiatherosclerotic drug development: Examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: Cholesterol acyltransferase inhibitor programs

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 459-466

  Stoekenbroek, Robert M ^a   Kastelein, John J P ^a   Hovingh, G Kees ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

acyl coenzyme A:cholesterol acyltransferase; cardiovascular disease; secretory phospholipase A2; thyromimetics

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CL 277081; DARAPLADIB; EPROTIROME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LECIMIBIDE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MB 07811; PACTIMIBE; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; SOBETIROME; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VARESPLADIB;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOALPHALIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORBIDITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT;

ANIMALS; ATHEROSCLEROSIS; DRUG DISCOVERY; HUMANS; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2, SECRETORY; RECEPTORS, THYROID HORMONE; STEROL O-ACYLTRANSFERASE;

EID: 84888298822     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000024     Document Type: Review

References (53)

1. Besseling J, van Capelleveen J, Kastelein JJ, Hovingh GK. LDL cholesterol goals in high-risk patients: How low do we go and how do we get there? Drugs 2013; 73:293-301.
2. Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WM. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995; 155:1490-1495.
3. Strisower B, Gofman JW, Galioni E, et al. Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels. J Clin Endocrinol Metab 1955; 15:73-80.
4. The Coronary Drug Project Research Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 1972; 220:996-1008.
5. Gullberg H, Rudling M, Saltó C, et al. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 2002; 16:1767-1777.
6. Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010; 21:499-506.
7. Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 1998; 249:517-521.
8. Tancevski I, Demetz E, Eller P, et al. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One 2010; 5:E8722.
9. Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci U S A 2005; 102:10297-10302. Mechanistic studies in mice showing the effects of TRE modulation
10. Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-145.
11. Baxter JD, Webb P. Thyroid hormone mimetics: Qotential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8:308-320.
12. Morkin E, Ladenson P, Goldman S, Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: Qast, present and future prospects. J Mol Cell Cardiol 2004; 37:1137-1146.
13. Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A 2008; 105:663-667. Pivotal study addressing the role of the 'new in class' agent KB21165.
14. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362:906-916. Seminal trial showing the effects of eprotirome
15. Williams GR. Thyroid hormone actions in cartilage and bone. Eur Thyroid J 2013; 2:3-13.
16. Meulenbelt I, Bos SD, Chapman K, et al. Meta-analyses of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Ann Rheum Dis 2011; 70:164-167.
17. Lewinson D, Harel Z, Shenzer P, et al. Effect of thyroid hormone and growth hormone on recovery from hypothyroidism of epiphyseal growth plate cartilage and its adjacent bone. Endocrinology 1989; 124:937-945.
18. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009; 50:237-242.
19. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J 2012; 33:2899-2909.
20. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: The EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007; 27:1177-1183.
21. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
22. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
23. Ivandic B, Castellani LW, Wang XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999; 19:1284-1290.
24. Webb NR, Bostrom MA, Szilvassy SJ, et al. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:263-268.
25. Sato H, Kato R, Isogai Y, et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008; 283:33483-33497.
26. Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group V secretory phospholipase A2 promotes atherosclerosis: Evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007; 27:600-606.
27. Kleinman Y, Krul ES, Burnes M, et al. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res 1988; 29:729-743.
28. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999; 274:25913-25920.
29. Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005; 32:417-423.
30. Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009; 53:60-65.
31. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomised, placebo-controlled trial. Lancet 2009; 373:649-658. Clinical trial showing the beneficial effects of A-002.
32. Rosenson RS, Elliot M, Stasiv Y, et al. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statintreated patients with coronary heart disease. Eur Heart J 2011; 32:999-1005.
33. Rosenson RS, Hislop C, Elliott M, et al. Effects of varespladib methyl on biomarkers and cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 2010; 56:1079-1088.
34. Dzavík V, Lavi S, Thorpe K, et al. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. Circulation 2010; 122:2411-2418.
35. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011; 162:613-619; e1.
36. Farese RV Jr. The nine lives of ACAT inhibitors. Arterioscler Thromb Vasc Biol 2006; 26:1684-1686.
37. Bocan TM, Mueller SB, Uhlendorf PD, et al. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Arterioscler Thromb 1991; 11:1830-1843.
38. Bocan TM, Mueller SB, Uhlendorf PD, et al. Inhibition of acyl-CoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig. Atherosclerosis 1993; 99:175-186.
39. Matsuo M, Ito F, Konto A, et al. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim Biophys Acta 1995; 1259:254-260.
40. Fazio S, Major AS, Swift LL, et al. Increased atherosclerosis in LDL receptornull mice lacking ACAT1 in macrophages. J Clin Invest 2001; 107:163-171.
41. Yagyu H, Kitamine T, Osuga J, et al. Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem 2000; 275:21324-21330.
42. Accad M, Smith SJ, Newland DL, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:Cholesterol acyltransferase 1. J Clin Invest 2000; 105:711-719.
43. Kusunoki J, Hansoty DK, Aragane K, et al. Acyl-CoA:Cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103:2604-2609.
44. Brewer HB Jr. The lipid-laden foam cell: An elusive target for therapeutic intervention. J Clin Invest 2000; 105:703-705.
45. Hainer JW, Terry JG, Connell JM, et al. Effect of the acyl-CoA:Cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther 1994; 56:65-74.
46. Harris WS, Dujovne CA, von Bergmann K, et al. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther 1990; 48:189-194.
47. Peck RW, Wiggs R, Posner J. The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA:Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Eur J Clin Pharmacol 1995; 49:243-249.
48. InsullWJr, Koren M, Davignon J, et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001; 157:137-144.
49. Raal FJ, Marais AD, Klepack E, et al. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003; 171:273-279. First trial in patients with homozygous familial hypercholesterolemia addressing the role of avasimibe
50. Tardif JC, Gré goire J, L'Allier PL, et al. Effects of the acyl coenzyme A:Cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004; 110:3372-3377.
51. Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354:1253-1263.
52. Meuwese MC, de Groot E, Duivenvoorden R, et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: The CAPTIVATE randomized trial. JAMA 2009; 301: 1131-1139. Landmark trial that likely resulted in stopping development of ACAT inhibitors
53. Parini P, Davis M, Lada AT, et al. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. JAMA 2009; 301:1131-1139.